Combinations of immunotherapy and vascular endothelial growth factor (VEGF) inhibitors have been proven to effective at improving survival for people with advanced or metastatic renal cell carcinoma (RCC). However, the role of a cytokine called interleukin-10 (IL-10) has been shown to enhance immunotherapy-induced anti-cancer activity. In this phase 1 trial, the safety, tolerability and preliminary […]
The origins of seven types of kidney cancer, including several rare subtypes, have been identified by researchers at the Wellcome Sanger Institute, Great Ormond Street Hospital (GOSH), the Princess Máxima Center for Paediatric Oncology and Oncode Institute. The findings confirm that these cancers originated in developmental cells found in the foetus. The results from the […]
A simple blood test that can detect more than 50 types of cancer is to be piloted by NHS England in the autumn. The test identifies circulating free DNA (cfDNA) from cancer before any clinical signs or symptoms of the disease emerge. It is hoped it will eventually become a screening test for the early […]
World Kidney Cancer Day 2021 takes place this Thursday 17 June. The theme of this year’s campaign is “We need to talk about how we’re feeling” to raise awareness and address the psychosocial issues experienced by kidney cancer patients, both within the UK and on a global scale. This campaign has been confounded by the current COVID-19 pandemic and the shielding of […]
The KEYNOTE-426 study of the immune checkpoint inhibitor, pembrolizumab plus the VEGF inhibitor, axitinib for advanced renal cell carcinoma continues to show survival benefits compared with sunitinib as a first treatment after surgery. In this oral presentation from the American Society for Clinical Oncology (ASCO) Annual Meeting, further follow-up data from KEYNOTE-426 over more than […]
Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are stopped from getting to the brain by a membrane called the blood-brain barrier. Most patients with brain metastases have, therefore, been excluded from phase 3 clinical trials. In the phase 3/4 CheckMate 920 study, presented at […]
Ongoing results from the phase 3 CheckMate-9ER clinical trial with nivolumab plus cabozantinib were presented a the American Society for Clinical Oncology (ASCO) Annual Meeting over the weekend. The nivolumab/cabozantinib combination doubled the average time to when the treatment stopped working and the cancer started growing again (progression-free survival) compared to sunitinib and nearly twice […]
The cabozantinib/nivolumab combination has been shown to be effective at improving survival in patients with metastatic clear cell renal cell carcinoma (RCC) in a phase 3 trial. This poster presentation from the American Society for Clinical Oncology (ASCO) Annual Meeting at the weekend reports the results of a phase 2 trial of cabozantinib/nivolumab in patients […]
Cell metabolism in renal cell carcinoma (RCC) tumours is disrupted, and RCC tumour cells tend to have high levels of an enzyme called glutaminase, a key enzyme for the metabolism of glutamine. Glutamine is an amino acid that is found in most proteins. It is a source of energy for cell growth. Telaglenastat is a […]
Results from the phase 3 CLEAR study were presented at the American Society for Clinical Oncology (ASCO) Annual Meeting at the weekend. Previous studies have shown that lenvatinib (VEGF inhibitor) used together with pembrolizumab (immune checkpoint inhibitor) resulted in better survival and cancer shrinkage compared to sunitinib when used for patients with advanced renal cell […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
